Business
OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma
OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, has selected EVERSANA®, a leading provider of global commercial services to the life sciences industry, to support the U.S. commercialization of OST-HER2, a novel immunotherapy for recurrent, fully resected, pediatric lung metastatic osteosarcoma.
About this update from Os Therapies Incorporated
[{"type":"text","content":"NEW YORK and CHICAGO, June 10, 2025 /PRNewswire/ -- OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, has selected EVERSANA®, a leading provider of global commercial services to the life sciences industry, to support the U.S. commercialization of OST-HER2, a novel immunotherapy for recurrent, fully resected, pediatric lung metastatic osteosarcoma.","length":481,"tagName":"p"},{"type":"image","alt":"OS Therapies (OST) is a clinical-stage cancer immunotherapy company dedicated to developing a new way of activating the immune system to kill cancers that express HER2 like Osteosarcoma, Breast Cancer, Colorectal Cancer and other solid tumors.","displaySize":"","headline":null,"caption":"OS Therapies (OST) is a clinical-stage cancer immunotherapy company dedicated to developing a new way of activating the immune system to kill cancers that express HER2 like Osteosarcoma, Breast Cancer, Colorectal Cancer and other solid tumors.","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":66,"url":"https://media.zenfs.com/en/prnewswire.com/cebdf2facab0fb952e18d01aeb85b5a7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WkxVR1tGNlThfDH9n.WEYA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTExNjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/cebdf2facab0fb952e18d01aeb85b5a7","width":400,"height":66}},"href":"https://mma.prnewswire.com/media/2706811/OS_Therapies.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"OST-HER2, a Listeria monocytogenes-based immunotherapy, is the first potential new treatment in over 40 years for pediatric osteosarcoma, a rare, aggressive bone cancer that often metastasizes to the lungs, primarily affecting children and adolescents. The therapy has received Orphan, Fast Track and Rare Pediatric Disease Designations from the U.S. Food and Drug Administration (FDA), with a Biologics License Application (BLA) rolling submission targeted to begin in the third quarter of 2025, with potential approval coming as early as year end 2025.","length":554,"tagName":"p"},{"type":"text","content":""Working with EVERSANA ensures we have the infrastructure, expertise and agility to bring OST-HER2 to patients and families who have long awaited new option...